Compare CNTN & DHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNTN | DHY |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | 3 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.2M | 208.3M |
| IPO Year | 2022 | 1998 |
| Metric | CNTN | DHY |
|---|---|---|
| Price | $3.28 | $1.89 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 429.9K | ★ 462.9K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.02 | $1.82 |
| 52 Week High | $5.27 | $2.16 |
| Indicator | CNTN | DHY |
|---|---|---|
| Relative Strength Index (RSI) | 35.92 | 48.17 |
| Support Level | $3.11 | $1.83 |
| Resistance Level | $3.51 | $2.14 |
| Average True Range (ATR) | 0.24 | 0.03 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 49.00 | 75.00 |
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company also operates a validator node on the Canton Network to facilitate transaction validation and network operations. It also operates a clinical-stage biotech research and development arm. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.
Credit Suisse High Yield Credit Fund is a diversified, closed-end management investment company. The Fund's principal investment objective is to generate current income. Capital appreciation is a secondary objective, pursued to the extent consistent with the Fund's primary income objective.